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1. Introduction 
Cardiovascular diseases (CVD) are one of the leading causes of death in world. Many 
epidemiological studies have concluded that a diet rich in fruits and vegetables reduces the 
incidence of heart disease in humans (Khachik et al., 2002). Carotenoids are important 
photochemical those are considered to be responsible for the health protective effects of 
fruits and vegetables (Omoni & Aluko, 2005). The carotenoids are a group of over 600 fat 
soluble pigments that are responsible for the natural yellow, orange, and red colors of fruits 
and vegetables (Giovannucci, 2002). Lycopene is one of such carotenoids, and is the pigment 
principally responsible for the distinctive red color of ripe tomato (Lycopersicon esculentum) 
and tomato products (Shi, 2000). Several epidemiological studies have suggested that a high 
consumption of tomatoes and tomato products containing lycopene may protect against 
CVD (Wu et al., 2003). These epidemiological leads have stimulated a number of animal 
model studies designed to test this hypothesis and to establish the beneficial effects of 
lycopene. Evidence from these studies suggests that lycopene has anti-atherogenic effects 
both in vitro and in vivo. The focus of this chapter is the anti-atherogenic effects of lycopene. 
This chapter will also highlight the chemical composition of lycopene, its sources and 
function, as well as potential impact an human health.     
2. Sources and function of lycopene  
Animals and humans do to not synthesize lycopene, and thus depend on dietary sources. 
Tomatoes and tomato products are the major dietary sources of lycopene. Other sources 
include watermelon, pink grapefruit, apricots, pink guava and papaya (Willis & Wians, 
2003). Lycopene is the most abundant carotenoid in ripe tomatoes, comprising 
approximately 80-90% of the pigments present. The amount of lycopene in fresh tomatoes 
depends on the variety, maturity, and environmental conditions in which the fruit matures 
(Shi, 2000).  
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Source  Lycopene content (mg/100g wet basis) 
Tomatoes fresh  0.72 – 20 
Tomato juice 5.00 – 11.60 
Tomato sauce  6.20 
Tomato paste  5.40 – 15.00 
Tomato soup 7.99 
Ketchup  9.90 – 13.44 
Pizza sauce  12.71 
Watermelon  2.30 – 7.20 
Pink guava 5.23 – 5.50 
Pink grapefruit 0.35 – 3.36 
Papaya  0.11 – 5.30 
Carrot  0.65 – 0.78 
Pumpkin  0.38 – 0.46 
Sweet potato  0.02 – 0.11 
Apricot  0.01- 0..05 
Table 1. shows the lycopene content of tomatoes, some commonly consumed tomato products and 
other lycopene containing fruits and vegetables. 
Lycopene is also widely distributed in the human body. It is one of the major carotenoids 
found in the human serum (between 21 and 43% of total carotenoids) with plasma levels 
ranging from 0.22 to 1.06 nmol/ml (Cohen, 2002). It is also found in various tissues 
throughout the body such as the liver, kidney, adrenal glands, tests, ovaries and the prostate 
gland (Basu & Imrhan, 2006). Unlike other carotenoids like α-and β-carotene, lycopene lacks 
the β.:onone rang structure common to other carotenooids (Agarwal & Rao, 2000). Although 
it lacks provitamine an activity, lycopene is known to be a potent antioxidant (Livny et al., 
2002). Reactive oxygen (ROS) species have been implicated in playing a major role in the 
causation and progression of several chronic diseases. These ROS are highly reactive 
oxidant molecules that are generated endogenously through regular metabolic activity. 
They react with cellular components, causing oxidative damage to such critical cellular 
biomolecules as lipids, proteins and DNA. Antioxidants are protective agents that inactive 
ROS and therefore, significantly delay or prevent oxidative damage associated with chronic 
disease risk. Lycopene is one of the most potent antioxidants among the dietary carotenoids 
and may help lower the risk of chronic diseases including cancer and heart disease. 
3. Chemical composition of lycopene 
Lycopene is a lipophelic, 40-carbon atom highly unsaturated, straight chain hydrocarbon 
containing 11 conjugated and 2 non-conjugated double bonds. The all-trans isomer of lycopene 
is the most predominant isomer in fresh tomatoes and is the most thermodynamically stable 
from (figure 1). The many conjugated double bonds of lycopene make it a potentially powerful 
antioxidant, a characteristic believed to be responsible for its beneficial effects. The antioxidant 
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activity of lycopene is high light by its singlet oxygen-quenching property and its ability to 
trap peroxy1 radicals. This singlet quenching ability of lycopene is twice as high as that of β-
carotene and 10 times higher than that of α-tocopherol and butylated hydroxyl toluene. 
 
Figure 1. All-trans Lycopene. 
As a result of the 11 conjugated carbon-carbon double bonds in its backbone, lycopene can 
theoretically assume 211 or 2048 geometrical configurations (Omani & Aluko, 2005).  
However, it is now known that the biosynthesis in plants leads to the all-trans-form, and this 
is independent of its thermodynamic stability. In human plasma, lycopene is an isomeric 
mixture, containing at least 60% of the total lycopene as cis- isomers ( Kim et al., 2012).  
All-trans, 5-cis, 9-cis, 13-cis, and 15-cis are the most commonly identified isomeric forms of 
lycopene with the stability sequence being 5-cis>all-trans>9-cis>13-cis>15- cis>7-cis>11-cis, 
(Agarwal & Rao, 2000) so that the 5-cis-form is thermodynamically more stable than the all-
trans-isomer. Whereas a large number of geometrical isomers are theoretically possible for 
all-trans lycopene, according to only certain ethylenic groups of a lycopene molecule can 
participate in cis-trans isomerization because of steric hindrance. In fact, only about 72 
lycopene cis isomers are structurally favorable. Figure 2 illustrates the structural distinctions 
of the predominant lycopene geometrical isomers. 
 
Figure 2. Geometrical isomers of lycopene 
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4. Mechanisms action of lycopene  
A cellular and molecular study have shown lycopene to be one of the most potent 
antioxidants and has been suggested to prevent atherogenesis by protecting critical 
bimolecules such as DNA, proteins, lipids and low density lipoproteins (Pool-zobel et al., 
1997). Lycopene, because of its high number of conjugated double bonds, exhibits higher 
singlet oxygen quenching ability compared to β-carotene or α-tocopherol (Di-Mascio et al., 
1989). Cis lycopene has been shown to predominate in both benign and malignant prostate 
tissues, suggesting a possible beneficial effect of high cis-isomer concentrations, and also the 
involvement of tissue isomerases in vivo isomerization from all trans to cis form (Clinton et 
al., 1996). Where as Levin et al., (1997) have shown that 9- cis- β-carotene is a better 
antioxidant than its all-trans counterpart, no such mechanistic data have been reported in 
case of individual lycopene isomers. Handley et al., (2003) reported a significant increase in 
5-cis lycopene concentrations following a 1- week lycopene-restricted diet, and a subsequent 
reduction in 5-cis, and a concomitant increase in cis-β, cis-D and cis-E lycopene isomers 
during the 15-day dietary intervention with tomato products in healthy individuals. 
Although this study reported a decrease in LDL oxidizability due to the intervention with 
tomato lycopene, the individual antioxidant role of lycopene isomers and their inter 
conversions remain unclear. At a physiological concentration of 0.3 μmol/1, lycopene has 
been shown to inhibit growth of non-neoplastic human prostate epithelial cells in vitro, 
through cell cycle arrest which may be of significant implications in preventing benign 
prostate hyperplasia, a risk factor for prostate cancer (Obermuller-Jevic et al., 2003). 
Lycopene has also been shown to significantly reduce LNCaP human prostate cancer cell 
survival in a dose-dependent manner, and this anti-neoplastic action may be explained by 
increased DNA damage at high lycopene concentrations (> 5μm), whereas lower levels of 
lycopene reduced malondialdehyde formation, with no effects on DNA (Hwang & Bowen, 
2005). Physiologically attainable concentrations of lycopene have been shown to induce 
mitochondrial apoptosis in LNCaP human prostate cancer cells, although no effects were 
observed on cellular proliferation or necrosis (Hantz et al., 2005). Lycopene has also been 
shown to interfere in lipid metabolism, lipid oxidation and corresponding development of 
atherosclerosis. Lycopene treatment has been shown to cause a 37% suppression of cellular 
cholesterol synthesis in J-774A.1 macrophage cell line, and augment the activity of 
macrophage LDL receptors (Fuhrman et al., 1997). Oxidized LDLs are highly atherogenic as 
they stimulate cholesterol accumulation and foam cell formation, initiating the fatty streaks 
of atherosclerosis (Libby, 2006). LDL susceptibility to oxidative modifications is decrease by 
an acyl analog of platelet-activating (PAF), acyl-PAF, which experts its beneficial role during 
the initiation and progression of atherosclerosis. Purified lycopene in association with α-
tocopherol or tomato lipophillic extracts has been shown to enhance acyl-PAF biosynthesis 
in endothelial cells during oxidative stress (Balestrieri et al., 2004). Fuhrman et al., (2000) 
further reported comparative data in which tomato oleoresin exhibited superior capacity to 
inhibit in vitro LDL oxidation in comparison with pure lycopene by up to fivefold. A 
combination of purified lycopene (5μmol/I) with α-toopherol in the concentration range of 
1-10μmol/I resulted in a significant greater inhibition of in vitro LDL oxidation, than the 
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expected additive individual inhibitions. In this study, purified lycopene was also shown to 
act synergistically with other natural antioxidants like the flavonoid glabridin, the phenolics 
rosmarinic acid and carnosic acid, and garlic acid in inhibiting LDL oxidation in vitro. These 
observations suggested a superior antiatherogeneic characteristic of tomato oleoresin over 
pure lycopene. The combination of lycopene with other natural antioxidants, as in tomatoes, 
may be more potent in inhibiting lipid peroxidation, than lycopene per se. The 
antiatherogenic effects of lycopene are generally believed to be due to its antioxidant 
properties. Dietary lycopene increases blood and tissue lycopene levels and acting as an 
antioxidant, lycopene traps reactive oxygen species and reduce the oxidative damage to 
lipids (lipoproteins and membrane lipids), proteins including important enzymes, and 
DNA, therapy lowering oxidative stress. This reduced oxidative stress then leads to a 
reduced risk for chronic diseases associated with oxidative stress such as cardiovascular 
disease (Omani & Aluko 2005). Alternatively, some non-oxidative mechanisms may be 
responsible for the beneficial effects of lycopene. The increased lycopene status in the body 
may regulate gene functions, improve intercellular communication, modulate hormone and 
immune response, or regulate metabolism, thus lowering the risk for chronic disease 
(Agarwl & Rao, 2000). A possible mechanism speculated for the protective role of lycopene 
in heart disease is via the inhibition of cellular HMGCoA reducate, the rate-limiting enzyme 
in cholesterol synthesis (Fuhrman et al., 1997). 
5. Lycopene stability  
Being acyclic, lycopene possesses symmetrical planarity and has no vitamin A activity, and 
as a highly conjugated polyene, it is particularly susceptible to oxidative degradation. 
Physical and chemical factors known to degrade other carotenoids, including elevated 
temperature, exposure to light, oxygen, extremes in pH, and molecules with active surfaces 
that can destabilize the double bonds, apply to lycopene as well (Rao et al., 2003). 
In a study to determine the photoprotective potential of dietary antioxidants including 
lycopene carried out by Handley et al., (2003) carotenoids were prepared in special 
nanoparticle formulations together with vitamin C and/or vitamin E. The presence of 
vitamin E in the formulation further increased the stability and cellular uptake of lycopene, 
which suggests that vitamin E in the nanoparticle, protects lycopene against oxidative 
transformation. Their findings suggest that lycopene stability may be improved by 
nanoparticle formulation and incorporation of vitamin E in the lycopene formulation. 
Badimon et al., 2010 studied the stability of lycopene during heating and illumination. They 
carried out various pretreatment steps to the all-trans lycopene standard, which included; 
dissolving the lycopene standard into hexane and evaporating to dryness under nitrogen in 
vials, after which a thin film formed at the bottom surface. The resulting lycopene was 
heated at 50, 100, and 150°C or illuminated at a distance of 30 cm with illumination intensity 
in the range of 2000–3000 lux (25°C) for varied lengths of time (up to100 hours for heating 
and 5 days for illumination). After analysis, the degradation of total lycopene (all-trans plus 
cis forms) during heating or illumination was found to fit a firstorder model. At 50°C, the 
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isomerization dominated in the first 9 hours; however, degradation was favored afterwards. 
At 100 and 150°C, the degradation proceeded faster than the isomerization, whereas, during 
illumination, isomerization was the main reaction. The degradation rate constant (min−1) of 
lycopene was found to rise with increasing temperature with an activation energy calculated 
as 61.0 kJ/mol. 
The stability of crystalline lycopene was determined under various temperature conditions 
(5, 25, and 35°C) while stored in airtight containers, sealed under inert gas, and protected 
from light. After 30 months of storage, crystalline lycopene remained stable when stored 
under the recommended conditions (Barros et al., 2011).  
Lycopene (synthetically prepared by the Wittig reaction) 5% TG (Tablet Grade) and 
lycopene 10% WS (Water Soluble) beadlet formulations tested for over 24 months of storage, 
and Lycopene 10% FS (Fluid Suspension) liquid formulation tested for over 12 months of 
storage under various temperature conditions (5 and 25°C), were all found to be stable.(25) 
For the 10% WS lycopene beadlet formulations, an important market application form, 
stability with respect to oxidation under ambient light conditions and room temperature for 
12 months in beverages was found to be 93% of the initial content of the beverage lycopene 
(Pool-zobel et al., 1997). 
6. Dietary intake of lycopene 
The human body is unable to synthesize carotenoids, which qualifies diet as the only source 
of these components in blood and tissues. At least 85% of our dietary lycopene comes from 
tomato fruit and tomato-based products, the remainder being obtained from other fruits 
such as watermelon, pink grapefruit, guava, and papaya, Tomatoes are an integral part of 
the human diet and are commonly consumed in fresh form or in processed form such as 
tomato juice, paste, puree, ketchup, soup, and sauce. Kim et al., (2012) used a tomato 
products consumption frequency questionnaire to estimate the average daily consumption 
of different tomato products in the Canadian population.  
Di-Mascio et al., (1989) estimated that 50% of the dietary lycopene was obtained from fresh 
tomatoes, while the average daily intake of lycopene was estimated to be 25 mg in the 
Canadian population. In a British study conducted with elderly females, the daily 
consumption of lycopene-rich food, such as tomatoes and baked beans in tomato sauce 
(measured by weight of foods eaten), was equivalent to a daily lycopene intake of 1.03 mg 
per person (Omani & Aluko, 2005) developed a database from which the carotenoid intake 
of the German population, stratified by sex and age, was evaluated on the basis of the 
German National Food Consumption Survey (NVS). The mean total carotenoid intake 
amounted to 5.33 mg/day. The average intake of lycopene was 1.28 mg/day with tomatoes 
and tomato products providing most of the lycopene. 
A study presenting data on dietary intake of specific carotenoids in The Netherlands, based on 
a food composition database for carotenoids, was done by Furhman et al., (1997). Regularly 
eaten vegetables, the main dietary source of carotenoids, were sampled comprehensively and 
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analyzed with modern analytic methods. The database was complemented with data from 
literature and information from food manufacturers. Intake of carotenoids was calculated for 
participants of the Dutch Cohort Study on diet and cancer, aged 55 to 69 in 1986, and the mean 
intake of lycopene was 1.0 mg/day for men and 1.3 mg/day for women. 
6.1. Bioavailability of lycopene 
Although 90% of the lycopene in dietary sources is found in the linear, all-trans 
conformation, human tissues (Particularly liver, adrenal, adipose tissue, testes and prostate) 
contain mainly cis-isomers. Hollowy et al., (2002) reported that a dietary supplementation of 
tomato pure for 2 weeks in healthy volunteers led to a completely different isomer pattern 
of plasma lycopene in these volunteers, versus those present in tomato pure. 5-cis, 13-cis and 
9-cis lycopene isomers, not detected in tomato puree, were predominant in the serum 
(Hollowary et al., 2000).Analysis of plasma lycopene in male participants in the health 
professionals follow-up study revealed 12 distinct cis-isomers and the total cis-lycopene 
contributed about 60-80% of total lycopene concentrations (Wu et al., 2003). Studies 
conducted with lymph cannulated ferrts have shown better absorption of cis-isomers and 
their subsequent enrichment in tissues (Boileau et al., 1999). Physiochemical studies also 
suggest that cis-isomer geometry accounts for more efficient incorporation of lycopene into 
mixed micelles in the lumen of the intestine and into chylomicrons by the enterocyte. Cis-
isomers are also preferentially incorporated by the liver into very low-density lipoprotein 
(VLDL) and get secreted into the blood (Britton, 1995). Research has shown convincing 
evidence regarding the isomerization of all trans-lycopene to cis-isomers, under acidic 
conditions of the gastric juice. Incubation of lycopene derived from capsules with simulated 
gastric juice for 1-min shown a 40% cis-lycopene content, whereas the levels did not exceed 
20% even after 3h incubation with water as a control. However, when tomato puree was 
incubated for 3h with simulated gastric juice, the cis-lycopene content was only 18% versus 
10% on incubation with water. Thus, gastric pH and food matrix influence isomerization 
and subsequent absorption and increased bioavailability of cis-lycopene (Re et al., 2001).  
The process of cooking which releases lycopene from the matrix into the lipid phase of the 
meal increases its bioavailability, and tomato paste and tomato puree are more bioavailable 
sources of lycopene than raw tomatoes (Gartner et al., 1997 & Porrini et al., 1998). Factors 
such as certain fibers, fat substituents, plant sterols and cholesterol-lowering drugs can 
interfere with the incorporation of lycopene into micelles, thus lowering its absorption 
(Boileau et al., 2002). Several clinical trials have also shown the bioavailability of lycopene 
from processed tomato products (Table 2). Agarwal and Rao (1998), reported a significant 
increase in serum lycopene levels following a 1-week daily, consumption of spaghetti sauce 
(39mg of lycopene), tomato juice (50mg of lycopene) or tomato oleoresin (75 or 150 mg of 
lycopene), in comparison with the placebo, in healthy human volunteers. There was also 
indication that the lycopene levels increased in a dose-dependent manner in the case of 
tomato sauce and tomato oleoresin. Reboul et al., (2005) further demonstrated that 
enrichment of tomato paste with 6% tomato peel increases lycopene bioavailability in men, 
thereby suggesting the beneficial effects of peel enrichment, which are usually eliminated 
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during tomato processing. Richelle et al., (2002) compared the bioavailability of lycopene 
from tomato paste and from lactolycopene formulation (Lycopene from tomato oleoresin 
embedded in a whey protein matrix), and reported similar bioavailability of lycopene from 
the two sources in healthy subjects. Dietary fat has been shown to promote lycopene 
absorption, principally via stimulating bile production for the formation of bile acid 
micelles. Consumption of tomato products with olive oil or sunflower oil has been shown to 
produce an identical bioavailability of lycopene, although plasma antioxidant activity 
improved with olive oil consumption, suggesting a favorable impact of monounsaturated 
fatty acids on lycopene absorption and its antioxidant mechanism (Lee et al., 2000). In an 
interesting study Unlu et al., (2005) reported the role of avocado lipids in enhancing 
lycopene absorption. In this study, in healthy, nonpregnant, nonsmoking adults, the 
addition of avocado oil (12 or 24g) to salsa (300g) enhanced lycopene absorption, resulting in 
4.4 times the mean area under the concentration-versus-time curve after intake of avocado-
free salsa. This study demonstrates the favorable impact of avocado consumption on 
lycopene absorption and has been attributed to the fatty acid distribution of avocados 
(66.00% oleic acid), which may facilitate the formation of chylomicrons. In a comparative 
study by Hoppe et al., (2003), both synthetic and tomato –based lycopene supplementation 
showed similar significant increases of serum total lycopene above baseline whereas no 
significant changes were found in the placebo group. In an attempt to study lycopene 
metabolism, Diwadkar-Navsariwala et al., (2003) developed a physiological pharmcokinetic 
model to describe the disposition of lycopene, administered as a tomato beverage 
formulation at five graded does (10, 30, 60, 90, or 120 mg) in healthy men. Blood was 
collected before dose administration and at scheduled study intervals until 672h. The overall 
results of this study showed that independent of dose, 80% of the subjects absorbed less 
than 6mg of lycopene, suggesting a possible saturation of absorptive mechanisms. This may 
have important implications for planning clinical trials with pharmacological doses of 
lycopene in the control and prevention of chronic disease, if absorption saturation occurs at 
normally consumed levels of dietary lycopene.  
6.2. The anti-atherogenic effects of lycopene 
In a previous study (Basuny et al., 2006 and 2009) was to study the effect of tomato lycopene 
on hypercholesterolemia. Lycopene of tomato wastes was extracted and determination. The 
level of tomato lycopene was 145.50ppm. An aliquots of the concentrated tomato lycopene, 
represent 100, 200, 400 and 800ppm; grade lycopene (200ppm) and butylated hydroxyl 
toluene (BHT, 200ppm) were investigated by 1,1-diphenyl-2-picrylhydrazyl (DPPH) free 
radical scavenging method. These compounds were administered to rats fed on 
hypercholestrolemic diet daily from 10 weeks by stomach tube. Serum lipid contents (total 
lipids, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein 
cholesterol), oxidative biomarkers (glutathione peroxidase and malonaldhyde), the liver 
(aspartate aminotransferase, alanine aminotranseferase and alkaline phosphatase activities) 
and kidney (uric acid, urea and creatinine) function testes were measured to assess the 
safety limits of the lycopene in tomato wastes. The data of the aforementioned 
measurements indicated that the administration of tomato lycopene did not cause any 
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changes in liver and kidney functions. On the contrary, rats fed on hypercholesterolemic 
diet induced significant increases in the enzymes activities and the serum levels of total lipids, 
total cholesterol and low and high density lipoproteins cholesterol and decreased levels of the 
glutathione peroxidase and malonaldhyde. In conclusion, presently available data from 
epidemiological and a number of animal studies have provided evidence to suggest that 
lycopene, the naturally present carotenoid in tomatoes and other fruits and vegetables, 
possesses anti-atherogenic effects. However, there is a need for more human dietary 
intervention studies in order to better understand the role of lycopene in human health.  
Scientific evidence indicates that oxidation of low density lipoprotein (LDL), which carry 
cholesterol in the blood stream plays an important role in the development of atherosclerosis, 
the underlying disorder leading to heart attacks and ischemic strokes (Rao, 2002). Several 
studies indicate that consuming the antioxidant lycopene that is contained in tomatoes and 
tomato lycopene products can reduce the risk of cardiovascular diseases (CVD). Available 
evidence from the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study suggests that the 
thickness of the innermost wall of blood vessels and the risk of myocardial infarction reduced 
in persons with higher serum and adipose tissue concentrations of lycopene (Rissanen et al., 
2003). This finding suggests that the serum lycopene concentration may play a role in the early 
stages of atherosclerosis. A thick artery wall is a sign of early atherosclerosis, and increased 
thickness of the intima media has been shown to predict coronary events. Similarly, the 
relationship between plasma lycopene concentration and intima-media thickness of the 
common carotid artery wall (CCA-IMT) was investigation in 520 middle-aged men and 
women 45-69 years as parts of the Antioxidant Supplementation in Atherosclerosis Prevention 
(ASAP) study (Rissanen et al., 2000). Low levels of plasma lycopene were associated with a 
17.80% increment in CCA-IMT in men, while there was no significant difference among 
women. These findings also suggest that low plasma lycopene concentrations are associated 
with early atherosclerosis, evidenced by increased CCA-IMT in middle-aged men.  
Findings from the Rotterdam Study (Klipstein-Grobusch et al., 2000) showed modest inverse 
associations between levels of serum lycopene and atherosclerosis, assessed by the presence 
of calcified plaques in the abdominal aorta. Study population comprised of 108 cases of aortic 
atherosclerosis and 109 controls aged 55 years and over. The association between serum 
lycopene levels and atherosclerosis was most pronounced among subjects who were current 
and former smokers. No association with risk of aortic calcification for the serum carotenoids 
α-carotene, β-carotene, lutein and zeaxanthin was observed. These results suggest that 
lycopene may play a protective role in the development of atherosclerosis. Results from the 
European Study of Antioxidant, Myocardial Infarction, and Cancer of the breast (the 
EURAMIC study) also show that men with the highest concentration of lycopene in their 
adipose tissue biopsy had a 48% reduction in risk of myocardial information compared with 
men with the lowest adipose lycopene concentrations (Kohlmeir et al., 1997). An increase in 
LDL oxidation is known to be associated with an increased risk of atherosclerosis and 
coronary heart disease (Parthasarathy, 1998). Agarwal and Rao (1998) investigated the effect 
of dietary supplementation of lycopene on LDL oxidation in 19 healthy human subjects. 
Dietary lycopene was provided using tomato juice, spaghetti sauce and tomato oleoresin for a 
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period of 1 week each. Blood samples were collected at the end of each treatment, and TBARS 
and conjugated dienes were measured to estimate LDL oxidation. In addition to significantly 
increasing serum lycopene levels by a least twofold, lycopene supplementation significantly 
reduced serum lipid peroxidation and LDL oxidation. The average decrease of LDL –TBARS 
and LDL-conjugated diene for the tomato products treatment over placebo was 25 and 13%, 
respectively. These results suggest significance for lycopene in decreasing risk for coronary 
heart disease. Results from the ongoing Women’s Health Study (WHS) showed that women 
with the highest intake of tomato-based foods rich in lycopene had a reduced risk for CVD 
compared to women with a low intake of those foods (Sesso et al., 2003). Results showed that 
women who consumed seven servings or more of tomato based foods like tomato sauce and 
pizza each week had a nearly 30% risk reduction in total CVD compared to the group with 
intakes of less than one serving per week. The researchers also found out that women who 
ate more than 10 servings per week had an even more pronounced reduction in risk (65%) for 
specific CVD outcomes such as heart attack or stroke. Though not statistically significant, the 
strongest association of dietary lycopene with CVD protection was seen among women with 
a median dietary lycopene intake of 20.20 mg/day, who had a 33% reduction in risk of the 
disease when compared with women with the lowest dietary lycopene intake (3.3 mg/day).  
Lycopene has also been shown to have a hypercholesterolemic effect both in vivo and in 
vitro. In a small dietary supplementation study, six healthy male subjects were fed 60 
mg/day lycopene for 3 months. At the end of the treatment period, a significant 14% 
reduction in plasma LDL cholesterol levels was observed in vivo with no effect on HDL 
cholesterol concentration (Fuhrman et al., 1997) & Lorenz et al., 2012).  
6.3. Safety of lycopene 
The safety issue for carotenoids attracted much attention after the publication of the β-carotene 
supplementation trials, which yielded negative results. It is interesting that in thus studies an 
increased risk for lung cancer was related to a 12- and 16 fold increase in β-carotene plasma 
levels due to supplementation. β-carotene plasma levels increased from 0.32μml before 
supplementation up to 3.90 and 5.90 μm, respectively. Rao et al., (2003), which showed no effect 
for β-carotene supplementation, only a 5-fold increase in the carotenoid serum level was 
achieved. Interestingly, the only study with positive results after supplementation with β-
carotene was achieved in linxian, a chinese community with very low carotenoid levels 
(0.11μm) before the intervention (Jonker et al., 2003). Although supplementation caused an 11-
fold increase in β-carotene level, the final concentration of β-carotene reached was a relatively 
low 1.5μm. Interestingly, reviewing many studies which measured serum levels of β-carotene 
and lycopene after supplementation suggests that β-carotene serum levels are significantly 
higher than those found for lycopene. Serum levels reached for β-carotene are around 3μm and 
may exceed 5μm after supplementation; on the other hand lycopene levels above 1.2μm are 
rarely seen even after long-term application. Moreover, the serum level achieved for lycopene 
was not directly correlated to the amount of the supplementation carotenoid (Nahum et el., 
2001). For example, supplemented as high as 75 mg/day did not increase lycopene serum levels 
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more than 1μm (Agarwl & Rao 1998). In conclusion, by some unknown mechanism, lycopene 
plasma levels after supplementation remain relatively low, which may provide a safety value. 
6.4. Lycopene relationship with other micronutrients 
When reviewing data related to the chemoprevention of various diseases, it become evident 
that the use of a single carotenoid, or any other micronutrient which has been successful in vitro 
and animal models, does not prove as favorable in human intervention studies. That is, there is 
no magic bullet. In fact, accumulating evidence suggests that a concerted, synergistic action of 
various micronutrients is, more likely to be the basis of the disease-prevention activity of a diet 
rich in vegetables and fruits. Indeed, the sources of lycopene used in most of the human studies 
reviewed there were either prepared tomato products or tomato extracts containing lycopene 
and other tomato micronutrients and carotenoids in various proportions. Pure lycopene has not 
been tested as a single in human prevention studies. On the other hand, many studies showing 
the beneficial effect of lycopene in alleviating chronic conditions have been conducted in which 
the subjects were provided with tomato-based foods, or tomato extracts, but not with the pure 
compound. For example, the oleoresin preparation used in many of these studies also contained 
other tomato carotenoids such as phytoene, phytofluene and β-carotene (Amir et al., 1999; 
Pastori et al., 1998 & Stahl et al., 1998). In a recent study (Bioleau et al., 2003) that compared the 
potency of freeze-dried whole tomatoes (tomato powder) or pure lycopene in a rat model of 
prostate cancer. Rats were treated with the carcinogen (N-methyl1-N-nitrosourea) combined 
with androgens to stimulate prostate carcinogenesis, and the ability of these two preparations 
containing lycopene to enhance survival was compared. Mortality with prostate cancer was 
lower by 25 % (p- 0.09) for rats fed the tomato powder diet than for rats fed control feed. 
Prostate cancer morality of rats fed our lycopene was similar to that of the control group. The 
authors concluded that consumption of tomato powder but not pure lycopene inhibited 
prostate carcinogenesis, suggesting that tomato products contain other compounds, besides 
lycopene, that modify prostate carcinogenesis.  
6.5. Epidemiologic studies: lycopene and cardiovascular diseases 
Epidemiological observations also report an inverse association between plasma of tissue 
lycopene levels and the incidence of cardiovascular diseases. In the Kuopio Ischemic Heart 
Disease Risk Factor Study, lower levels of plasma lycopene were seen in men who had a 
coronary event compared with men who did not. In addition, a higher concentration of serum 
lycopene was inversely correlated with a decrease in the mean and maximal intima-mediated 
thickness of the common carotid artery (CCA-IMT) with lo lycopene, resulting in an 18% 
increase in CCA-IMT (Rissanen et al., 2003). The European Multiccnter Case-Control Study on 
antioxidants, Myocardial Infarction and Breast Cancer Study (EURAMIC Study) reported that 
a higher lycopene concentration was independently protective against cardiovascular diseases 
(Basu & Imrhan 2006). The Women’s Health Study further revealed that a decreased risk for 
developing cardiovascular diseases was more strongly associated with higher tomato intake 
than with lycopene intake (Sesso et al., 2003). Processed tomato products definitely provide a 
bioavailability source of lycopene and have a positive correlation with plasma and tissue 
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lycopene levels. However, these studies do not suggest a role of lycopene perse, in reducing 
the risks for cardiovascular diseases, as plasma level of lycopene, in epidemiologic studies, 
only reflects the consumption of tomato and tomato products. 
7. Conclusion 
Thus, it can be concluded that moderate amounts of whole food-based supplementation  
(2–4 servings) of tomato soup, tomato puree, tomato paste, tomato juice or other tomato 
beverages, consumed with dietary fats, such as olive oil or avocados, leads to increases in plasma 
carotenoids, particu- larly lycopene. The recommended daily intake of lycopene has been set at 
35 mg that can be obtained by consuming two glasses of tomato juice or through a combination 
of tomato products (Rao and Agarwal, 2000). These foods may have both chemopreventive as 
well as chemotherapeutic values as outlined in Figure 3. In the light of recent clinical trials, a 
combination of naturally occurring carotenoids, including lycopene, in food sources and 
supplements, is a better approach to disease prevention and therapy, versus a single nutrient. 
Lycopene has shown distinct antioxidant and anticarcinogenic effects at cellular levels, and 
definitely contributes to the health benefits of consumption of tomato products. However, until 
further research establishes sig- nificant health benefits of lycopene supplementation per se, in 
humans, the conclusion may be drawn that consumption of naturally occurring carotenoid-rich 
fruits and vegetables, particularly processed tomato products containing lycopene, should be 
encouraged, with positive implications in health and disease. 
 
Figure 3. Summary of mechanisms of action of tomato products or tomato oleoresin supplementation, 
containing lycopene, in health and disease. 
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 Type and duration of 
lycopene supplementation
Effects on biomarkers of 
oxidative stress/ 
carcinogenesis 
 
Agarwal and 
Rao 
(1998) 
19 healthy subjects 
(mean age 29 years, BMI 
2472.8 kg/m2) 
0 mg lycopene (placebo), 39 
mg lycopene (spaghetti 
sauce), 50 mg lycopene 
(tomato juice), or 75 mg 
lycopene (tomato oleoresin) 
per day for 1 week 
25% decrease in LDL-
TBARS 13% 
decrease in LDL-CD for 
all groups versus 
Increase at 7 days in 
all groups versus 
placebo (P<0.05) 
 placebo (P<0.05)  
  
Riso et al. 
(1999) 
10 healthy subjects 
(mean age 23.171.1 years, 
BMI 20.571.5 kg/m2) 
16.5 mg lycopene (60 g 
tomato puree), per day for 
21 days 
38% decrease in DNA 
damage in lymphocytes 
(P<0.05) 
Increase at 21 days 
versus baseline 
(P<0.001) 
Bub et al. 
(2000) 
23 healthy volunteers 
(mean age 
3474 years, BMI 2372 
kg/m2) 
40 mg lycopene (330 ml
tomato juice) for 
2 weeks 
12% decrease in plasma 
TBARS 18% increase in 
LDL lag time (P<0.05) no
effects on water-soluble 
antioxidants, FRAP, 
glutathione peroxidase 
and reductase activities 
(P<0.05) 
Increase at 2 weeks 
versus baseline 
(P<0.05) 
  
  
  
Chopra et al. 
(2000) 
34 healthy females 
(mean age 
37.578.5 years, BMI 
2473.5 kg/m2) 
440 mg lycopene (200 g 
tomato 
puree þ 100 g watermelon) 
per day for 7 days 
Significant decrease in 
LDL oxidizability in 
nonsmokers (P<0.05); no 
effects in smokers (P<0.05)
Increase at 7 days 
versus baseline 
(P<0.05) 
Porrini and 
Riso 
(2000) 
9 healthy subjects (mean 
age 25.472.2years, BMI 
20.371.5 kg/m2) 
7 mg lycopene (25 g tomato 
puree), per day for 14 days
50% decrease in DNA 
damage in lymphocytes 
(P<0.05) 
Increase at 14 days 
versus baseline 
(P<0.001) 
Upritchard 
et al. 
15 well-controlled type 
II diabetics 
Tomato juice (500 ml) per 
day or placebo 
Decreased LDL 
oxidizability versus 
Increase at 4 weeks 
versus baseline 
(2000) (mean age 6378years, 
BMI30.977 kg/m2) 
for 4 weeks baseline (P<0.001) (P<0.001) 
Hininger et 
al. (2001) 
175 healthy volunteers 
(mean age 
33.571 years, BMI- 
24.370.5 kg/m2) 
15 mg lycopene (natural 
tomato extract) 
or placebo per day for 12 
weeks 
No effects on LDL 
oxidation, reduced 
glutathione, protein SH 
groups and antioxidant 
metalloenzyme activities
(P<0.05) 
Increase at 12 weeks 
versus baseline 
(P<0.05) 
  
  
Chen et al. 
(2001) 
32 patients with 
localized prostate 
30 mg lycopene (200 g 
spaghetti sauce) per day for 
3 weeks before surgery or a
reference group with no 
supplementation 
Decreased leukocyte and 
prostate tissue 
Increase at 3 weeks 
versus baseline 
 adenocarcinoma (mean 
age 63.776.1 years, BMI 
28.074.9 kg/m2) 
oxidative DNA damage; 
decreased serum PSA 
levels (P<0.05) 
(P<0.001) 
Kucuk et al. 
(2001) 
26 patients with newly 
diagnosed, clinically 
localized prostate cancer
(mean age 62.1571.85 
years, BMI not reported)
15 mg lycopene (Lyc-O-
Mato capsules) twice daily 
or no supplementation for 
3 weeks before surgery 
Decreased tumor growth 
in the intervention group 
versus control(P<0.05); 
decreased plasma PSA 
levels and increased 
expression of connexin43 
in prostate tissue in the 
intervention group 
versus control 
(P<0.05);decreased 
plasma IGF-1 levels in 
intervention and control 
groups(P<0.05) 
No effects at 3 weeks 
versus baseline 
(P<0.05)  
 
  
  
  
  
  
  
 
Lipoproteins – Role in Health and Diseases 502 
 Type and duration of 
lycopene supplementation
Effects on biomarkers of 
oxidative stress/ 
carcinogenesis 
 
Porrini et al. 
(2002) 
9 healthy subjects (mean 
age 
25.272.2 years, BMI 
20.271.6 kg/m2) 
7 mg lycopene (25 g tomato
puree) with 
150 g of spinach and 10 g of 
olive oil per 
day for 3 weeks 
Decreased DNA 
oxidative damage 
(P<0.05) 
Not reported 
    
Table 2. Summary of clinical trials investigating the effects of supplementation of tomato products, 
tomato oleoresin or purified lycopene on biomarkers of oxidative stress and Carcinogenesis 
Author details 
Amany M. M. Basuny 
Department of Fats & Oils, Food Technology Research Institute,  
Agriculture Research Centre, Giza, Egypt 
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